2009-2015: Pursued integrated Master's and Ph.D. studies at the Institute of Biophysics, Chinese Academy of Sciences, in the Infection and Immunity Research Center under the guidance of Professor Shengdian Wang.
Subsequently, conducted postdoctoral research and served as a research assistant at the Children's National Medical Center and the University of Maryland School of Medicine, under the mentorship of Professors Yang Liu and Pan Zheng.
Joined the Department of Immunology, School of Basic Medicine, Shandong University on August 27, 2021, establishing the Shandong University Tumor Immunology Team and serving as an independent PI.
Editorial Board Member of Fundamental Research (National Natural Science Foundation of China) and Cancer Advances (Chinese Anti-Cancer Association).
Review Editor for T Cell Biology and Antigen Presenting Cell Biology at Frontiers in Immunology.
Reviewer for the National Natural Science Foundation of China's Youth, General Program, and Regional projects, as well as multiple projects for the Provincial Department of Science and Technology.
The ADCC-enhanced, pH-sensitive CTLA-4 antibody ONC-392, developed based on novel mechanisms of anticancer activity and irAEs, is in international clinical trials (NCT04140526/NCT05446298/NCT05682443/NCT05671510/CTR20202042/CTR20223247).
ONC-392 received Fast Track designation by the FDA on April 26, 2022, for monotherapy in metastatic NSCLC patients refractory to PD-(L)1 antibody therapy.
On February 9, 2023, the Phase 1b clinical study of ONC-392 for liver, stomach, esophageal, and anal cancer commenced at Sun Yat-sen University Cancer Center, led by Dean Ruihua Xu.
On September 15, 2023, the registration for a Chinese Phase III lung cancer clinical trial was completed, initiating an international multicenter trial across 91 hospitals in Europe, the United States, Canada, South Korea, and China, chaired by Professor Yilong Wu of Guangdong Provincial People's Hospital.
On March 20, 2023, BioNTech and OncoC4 announced a strategic partnership, with BioNTech acquiring global rights to ONC-392. OncoC4 received a $200 million upfront payment and is eligible for additional milestone payments and double-digit sales royalties.
The CD24Fc, for the treatment of irAEs, has entered Phase I/II clinical trials in the United States (NCT04552704).
The CTLA-4-Ig mutant developed for the treatment and prevention of irAEs has been patented internationally (WO2018053506A1).
The team will further validate and develop new cancer immunotherapy strategies based on potential targets and biomarkers identified through second-generation sequencing data from mouse tumor models and clinical samples.
They will explore the mechanism of a candidate gene mutation associated with CTLA-4 antibody therapy response and validate its potential as a biomarker in new clinical trials.
Clinical exploratory trials will continue to investigate biomarkers for effective and safe CTLA-4 antibody therapy and reasons for non-response in some patients.
Two pioneering irAEs animal models will be used to explore new strategies and mechanisms to reduce irAEs without compromising antitumor immunotherapy efficacy.
The team will investigate new mechanisms of Anti-Drug-Antibody (ADA) production to develop safer and more effective humanized antibodies.
They will explore the connection between CTLA-4 and 4-1bb to discover new combination strategies for improving the efficacy and safety of antibody therapy for cancer.
2009-2015: Pursued integrated Master's and Ph.D. studies at the Institute of Biophysics, Chinese Academy of Sciences, in the Infection and Immunity Research Center under the guidance of Professor Shengdian Wang.
Subsequently, conducted postdoctoral research and served as a research assistant at the Children's National Medical Center and the University of Maryland School of Medicine, under the mentorship of Professors Yang Liu and Pan Zheng.
Joined the Department of Immunology, School of Basic Medicine, Shandong University on August 27, 2021, establishing the Shandong University Tumor Immunology Team and serving as an independent PI.
Editorial Board Member of Fundamental Research (National Natural Science Foundation of China) and Cancer Advances (Chinese Anti-Cancer Association).
Review Editor for T Cell Biology and Antigen Presenting Cell Biology at Frontiers in Immunology.
Reviewer for the National Natural Science Foundation of China's Youth, General Program, and Regional projects, as well as multiple projects for the Provincial Department of Science and Technology.
The ADCC-enhanced, pH-sensitive CTLA-4 antibody ONC-392, developed based on novel mechanisms of anticancer activity and irAEs, is in international clinical trials (NCT04140526/NCT05446298/NCT05682443/NCT05671510/CTR20202042/CTR20223247).
ONC-392 received Fast Track designation by the FDA on April 26, 2022, for monotherapy in metastatic NSCLC patients refractory to PD-(L)1 antibody therapy.
On February 9, 2023, the Phase 1b clinical study of ONC-392 for liver, stomach, esophageal, and anal cancer commenced at Sun Yat-sen University Cancer Center, led by Dean Ruihua Xu.
On September 15, 2023, the registration for a Chinese Phase III lung cancer clinical trial was completed, initiating an international multicenter trial across 91 hospitals in Europe, the United States, Canada, South Korea, and China, chaired by Professor Yilong Wu of Guangdong Provincial People's Hospital.
On March 20, 2023, BioNTech and OncoC4 announced a strategic partnership, with BioNTech acquiring global rights to ONC-392. OncoC4 received a $200 million upfront payment and is eligible for additional milestone payments and double-digit sales royalties.
The CD24Fc, for the treatment of irAEs, has entered Phase I/II clinical trials in the United States (NCT04552704).
The CTLA-4-Ig mutant developed for the treatment and prevention of irAEs has been patented internationally (WO2018053506A1).
The team will further validate and develop new cancer immunotherapy strategies based on potential targets and biomarkers identified through second-generation sequencing data from mouse tumor models and clinical samples.
They will explore the mechanism of a candidate gene mutation associated with CTLA-4 antibody therapy response and validate its potential as a biomarker in new clinical trials.
Clinical exploratory trials will continue to investigate biomarkers for effective and safe CTLA-4 antibody therapy and reasons for non-response in some patients.
Two pioneering irAEs animal models will be used to explore new strategies and mechanisms to reduce irAEs without compromising antitumor immunotherapy efficacy.
The team will investigate new mechanisms of Anti-Drug-Antibody (ADA) production to develop safer and more effective humanized antibodies.
They will explore the connection between CTLA-4 and 4-1bb to discover new combination strategies for improving the efficacy and safety of antibody therapy for cancer.
1. 重新评估并阐明CTLA-4抗体抗肿瘤的主要作用机制，为提高肿瘤免疫治疗有效性提供理论基础，助力研发更有效的CTLA-4抗体。
2. 建立能够模拟临床CTLA-4抗体治疗导致的免疫相关副作用的最佳动物模型，提出抗肿瘤效果与免疫相关副作用非关联存在的新理论，以此为基础研制的第二代CTLA-4抗体已经在美国和中国开展癌症病人临床试验。
3. 首次发现抗体的pH敏感性与副作用相关，揭示了CTLA-4抗体产生免疫相关副作用新机制，同时探索出多种减少副作用新方案。
4. 发现IL-21和HyperIL-15通过改变免疫抑制性微环境打破肿瘤免疫耐受，促进肿瘤抗原特异T细胞的功能治疗肿瘤，进一步提高治疗有效性。
